Aurobindo Pharma witnessed a nearly 9% surge in consolidated net profit for Q2FY25, reaching Rs 817 crore. This growth was fueled by an 8% rise in consolidated revenue, driven by a strong performance in formulations, particularly in the US and European markets. However, ARV revenues declined, and API revenues saw a marginal dip.
Related Posts
Bajaj Fin aims to double productivity with AI
Bajaj Finance is leveraging AI to boost its business. Their FinAI initiative aims to triple lead conversions, double back-office productivity, and improve front-line performance. AI […]
Dabur India’s drops more than 7% after forecasting first revenue decline in 4 years
Dabur India’s shares fell by up to 7.8% after a revenue decline for the first time in four years. The company attributed this to weak […]
Speculation over RBI chief Shaktikanta Das’ future heats up after GDP miss
Economists are speculating over the future of Das in the wake of data showing the South Asian economy expanded 5.4% from July to September, a […]